News
October 2, 2018
Montréal, October 2, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the election of François Legault and the Coalition Avenir Québec in Quebec on Monday :
October 1, 2018
Toronto, October 1, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA):
September 24, 2018
Toronto, September 24, 2018 – A new poll confirms that Canadians do not want their access to generic and biosimilar medicines traded away under a new NAFTA deal.
September 20, 2018
September 6, 2018 The Honourable Chrystia Freeland Minister of Foreign Affairs 125 Sussex Drive Ottawa, Ontario K1A 0G2 Re: Access to Affordable Medicines and NAFTA
September 19, 2018
The intellectual-property provisions included in the final agreement could delay when cost-saving generic and biosimilar medicines can enter the Canadian market, writes the president of the Canadian Generic Pharmaceutical Association.
September 5, 2018
Toronto, September 5, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the resumption of trade negotiations between the United States and Canada:
August 28, 2018
Toronto, August 28, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the preliminary agreement-in-principle announced August 27, 2018 between the United States and Mexico:
April 9, 2018
The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Mr. Peter Hardwick, Chief Commercial Officer and Executive Vice President of Apotex, as Chair of CGPA.
January 29, 2018
On behalf of participating federal, provincial, and territorial public drug plans, the pan-Canadian Pharmaceutical Alliance (pCPA), with the Canadian Generic Pharmaceutical Association (CGPA) have jointly developed a new five-year initiative that will provide significant savings for all Canadians who use prescription generic drugs, participating public drug plans, and employee drug plans.